The global antifungal drugs market is expected to grow from US$ 11,135.3 million in 2021 to US$ 13,997.4 million in 2028; it is estimated to grow at a CAGR of 3.3% from 2022 to 2028.
Antifungal drugs are used for treating common fungal infections such as fungal nail infections and vaginal infections that appear on the external surface of the body and other fungal invasive infections that occur inside the tissue of the body or in an internal organ such as the lungs and brains. It works against the fungal infection by either killing the fungal cells or constraining their growth.
The antifungal drugs market is attributed to the rising prevalence of fungal infections; increasing incidences of cancers, HIV, and hospital-acquired infections; and favorable government initiatives to combat the antifungal diseases. However, a lack of awareness regarding fungal infections is hampering the growth of the market.
The antifungal drugs market is segmented on the basis of infection type, drug type, therapeutic indication, dosage form, and geography. The report offers insights and in-depth analysis of the antifungal drugs market, emphasizing various parameters such as market trends, technological advancements, and market dynamics, as well as the competitive landscape analysis of leading market players.
Strategic Insights
Lucrative Regions of Antifungal Drugs Market
(image) Market Insights
Rising Prevalence of Fungal Infections Bolsters Antifungal Drugs Market Growth
Fungal infections are mainly caused due to microscopic fungi, which are commonly found in the atmosphere. According to the Centers for Disease Control and Prevention (CDC), in the US, from 2013 to 2017, the average incidence of fungal infection was ~9 per 100,000 people. Candidemia is among the most common bloodstream infections in the US. CDC predicts that approximately 25,000 cases of candidemia occur across the country every year. There has been significant variation in the rates of candidemia by age group. The rates have reduced considerably in infants. Candidemia rates are majorly high in people aged above 65 and older. The difference in the incidence of candidemia is due to age, race, alteration in underlying circumstances, socioeconomic status, and other factors.
Moreover, due to the tropical climate, South Asia has a high frequency of fungal infections. For instance, according to a report published by the Down To Earth organization in 2015, infection from yeast is 0.8 among 1,000 patients in the US. Moreover, the incidence is 0.2 and 0.9 per 1,000 patients in Europe and Australia, respectively. However, in India, approximately 1-12 cases occur in every 1,000 patients that are affected by the fungal infection. Therefore, the demand for antifungal drugs is increasing owing to providing treatment that helps maintain the proper immunity of the patients. Thus, the rising cases of fungal infections is likely to drive the market for antifungal drugs in the coming years.
Infection Type-Based Insights
Based on infection type, the global antifungal drugs market is bifurcated into superficial fungal infection and systemic antifungal infection. In 2018, the superficial fungal infection segment held a larger share of the market, and it is also expected to grow at the fastest rate during the forecast period. The rising prevalence of fungal infection of the skin, nails, and hair is likely to increase the growth of the antifungal drugs market during the forecast period.
Antifungal Drugs Market, by Type – 2021 and 2028
(image)
Drug Type-Based Insights
Based on drug type, the global antifungal drugs market is segmented into echinocandis, azoles, polyenes, allylamines, and others. In 2021, the azoles segment held the largest share of the market. However, the polyenes segment is expected to grow at the fastest rate during the forecast period.
Therapeutic Indication-Based Insights
Based on therapeutic indication, the global antifungal drugs market is segmented into aspergillosis, dermatophytosis, candidiasis, and others. In 2021, the candidiasis segment held the largest share of the market. However, the dermatophytosis segment is expected to grow at the fastest rate during the coming years.
Dosage Form-Based Insights
based on dosage form, the global antifungal drugs market is segmented into drugs, ointment, powder, and others. In 2021, the drugs segment held the largest share of the market, and it is expected to grow at the fastest rate during the coming years.
The Asia Pacific antifungal drugs market is expected to grow at the fastest rate during the forecast period. The market is estimated to grow during the forecast period due to the growing pharmaceutical industry in the countries such as China, Japan, and India. China's pharmaceutical industry is among the largest pharmaceutical industry across the globe. The country has shown significant growth in active pharmaceutical ingredient manufacturing, competitiveness, innovations, and final dosage formation. Hence, most multinational companies are showing interest in the Chinese market for drug sales.
In 2021, North America held the largest share of the antifungal drugs market. The North America antifungal drugs market is studied based on the three major countries—the US, Canada, and Mexico. The market growth in the region is majorly contributed by rising cases of fungal infections across the countries and growing awareness programs such as ‘Fungal Disease Awareness Week’. In addition, Mexico is expected to offer several growth opportunities in the coming years due to the rising prevalence of fungal diseases. For instance, according to an article published in the Brazilian Journal of Infectious Diseases in 2018, states that invasive fungal infections affect more than 1.5 million people per year in Mexico.
By geography, the antifungal drugs market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Company Profiles
- Pfizer Inc.
- Sanofi S.A.
- Gilead Sciences, Inc.
- Merck And Co., Inc.
- Scynexis Inc.
- Novartis International AG
- Abbott Laboratories
- Bayer AG
- Glenmark Pharmaceutical
- Glaxosmithkline Plc.